US generics tariffs more negotiation tactic than real threat: Biocon’s Kiran Mazumdar-Shaw

Biocon’s Kiran Mazumdar-Shaw said US generic tariffs are more a negotiation tactic than a real threat. In July, US President Donald Trump proposed a phased tariff plan for imported generic drugs. Shaw believes the plan is unviable as the US relies heavily on generics to keep healthcare costs low.